The National Academies of Sciences, Engineering, and Medicine established the National Cancer Policy Forum (NCPF) to serve as a trusted venue in which experts can work collaboratively to identify emerging high-priority policy issues in cancer research and care and to examine those issues through convening activities that promote discussion about opportunities for action.

These activities inform stakeholders about critical policy issues through published reports and often provide input for formal consensus committee studies. The NCPF provides a continual focus within the National Academies on cancer, addressing issues in science, clinical medicine, public health, and public policy that are relevant to the goal of reducing the cancer burden, both through prevention and by improving the care and outcomes for those diagnosed with cancer.

The NCPF has 38 members with a broad range of expertise in cancer, including patient advocates; clinicians; and basic, translational, and clinical scientists. Members represent federal agencies, academia, professional organizations, nonprofits, and industry. The forum has addressed a wide array of topics, including:

- enhancing collaborations to accelerate research and development;
- improving the quality and value of cancer care and survivorship care;
- developing tools and technologies to enhance cancer research and care; and
- examining factors that influence cancer incidence and mortality.
WORKSHOP PROCEEDINGS, 2007–2017

2017
The Drug Development Paradigm in Oncology: Proceedings of a Workshop
Cancer Care in Low-Resource Areas: Cancer Treatment, Palliative Care, and Survivorship Care: Proceedings of a Workshop
Implementation of Lung Cancer Screening: Proceedings of a Workshop

2016
Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer Treatment: Proceedings of a Workshop
Cancer Care in Low-Resource Areas: Cancer Prevention and Early Detection: Workshop Summary
Appropriate Use of Advanced Technologies for Radiation Therapy and Surgery in Oncology: Workshop Summary

2015
Comprehensive Cancer Care for Children and Their Families: Summary of a Joint Workshop by the IOM and the ACS
Policy Issues in the Development & Adoption of Biomarkers for Molecularly Targeted Cancer Therapies: Workshop Summary
Assessing and Improving the Interpretation of Breast Images: Workshop Summary
Role of Clinical Studies for Pets with Naturally Occurring Tumors in Translational Cancer Research: Workshop Summary

2014
Ensuring Patient Access to Affordable Cancer Drugs: Workshop Summary
Contemporary Issues for Protecting Patients in Cancer Research: Workshop Summary

2013
Identifying and Addressing the Needs of Adolescents and Young Adults with Cancer: Workshop Summary
Implementing a National Cancer Clinical Trials System for the 21st Century: Workshop Summary
Sharing Clinical Research Data: Workshop Summary
Delivering Affordable Cancer Care in the 21st Century: Workshop Summary
Reducing Tobacco-Related Cancer Incidence and Mortality: Workshop Summary

2012
The Role of Obesity in Cancer Survival and Recurrence: Workshop Summary
Informatics Needs and Challenges in Cancer Research: Workshop Summary
Facilitating Collaborations to Develop Combination Investigational Cancer Therapies: Workshop Summary

2011
Patient-Centered Cancer Treatment Planning: Improving the Quality of Oncology Care: Workshop Summary
The National Cancer Policy Summit: Opportunities and Challenges in Cancer Research and Care: Workshop Proceedings
Nanotechnology and Oncology: Workshop Summary

2010
Direct to Consumer Genetic Testing (with the National Research Council): Summary of a Workshop
Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary
A Foundation for Evidence-Driven Practice: A Rapid Learning System for Cancer Care: Workshop Summary
Policy Issues in the Development of Personalized Medicine in Oncology: Workshop Summary

2009
Assessing and Improving Value in Cancer Care: Workshop Summary
Ensuring Quality Cancer Care Through the Oncology Workforce: Sustaining Care in the 21st Century: Workshop Summary
Multi-Center Phase III Clinical Trials and the NCI Cooperative Group Program: Workshop Summary

2008
Implementing Colorectal Cancer Screening: Workshop Summary
Improving the Quality of Cancer Clinical Trials: Workshop Summary

2007
Cancer-Related Genetic Testing and Counseling: Workshop Proceedings
Cancer in Elderly People: Workshop Proceedings
Implementing Cancer Survivorship Care Planning: Workshop Summary
CONSENSUS STUDIES

Building on the Work of the NCPF

Ensuring Patient Access to Affordable Drug Therapies

This study is examining patient access to affordable and effective drug therapies, with an emphasis on drug pricing and insurance design. The study committee will issue a report, anticipated to release summer 2017, with findings and recommendations for policy actions that could address drug cost trends, improve patient access to affordable and effective treatments, and encourage innovation to address significant needs in health care.

Study website: nationalacademies.org/affordabledrugs

A National Strategy for Cancer Control in the United States

The National Academies is developing plans for a new consensus study that will examine existing cancer control efforts in the United States and recommend national strategies to reduce the incidence, morbidity, and mortality from cancer and to improve quality of life for cancer survivors.

PAST CONSENSUS STUDY REPORTS THAT BUILT ON NCPF WORK

Biomarker Tests for Molecularly Targeted Therapies: Key to Unlocking Precision Medicine (2016)
Report: nap.edu/catalog/21860

Ovarian Cancers: Evolving Paradigms in Research and Care (2016)
Report: nap.edu/catalog/21841

Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis (2013)
Report: nap.edu/catalog/18359

Evolution of Translational Omics: Lessons Learned and the Path Forward (2012)
Report: nap.edu/catalog/13297

A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program (2010)
Report: nap.edu/catalog/12879

Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease (2010)
Report: nap.edu/catalog/12869

Beyond the HIPAA Privacy Rule: Enhancing Privacy, Improving Health Through Research (2009)
Report: nap.edu/catalog/12458

Cancer Biomarkers: The Promises and Challenges of Improving Detection and Treatment (2007)
Report: nap.edu/read/11892
FORUM SPONSORS

- Centers for Disease Control and Prevention
- National Institutes of Health/National Cancer Institute
- American Association for Cancer Research
- American Cancer Society
- American College of Radiology
- American Society for Radiation Oncology
- American Society of Clinical Oncology
- American Society of Hematology
- Association of American Cancer Institutes
- AstraZeneca
- Bristol-Myers Squibb
- Cancer Support Community
- CEO Roundtable on Cancer
- Flatiron Health
- Helsinn Healthcare SA
- LIVESTRONG Foundation
- Merck
- National Comprehensive Cancer Network
- Novartis Oncology
- Oncology Nursing Society
- Pfizer, Inc.

MEMBERSHIP OF THE FORUM

Edward J. Benz, Jr., M.D. (Chair)
Dana-Farber Cancer Institute

Amy P. Abernethy, M.D.
Flatiron Health

Lucile L. Adams-Campbell, Ph.D.
Georgetown University

Garnet Anderson, Ph.D.
Fred Hutchinson Cancer Research Center

Kenneth Anderson, M.D.
Dana-Farber Cancer Institute

Karen Basen-Engquist, Ph.D., M.P.H.
The University of Texas MD Anderson Cancer Center

Cathy Bradley, Ph.D.
University of Colorado Cancer Center

Otis W. Brawley, M.D.
American Cancer Society

Robert W. Carlson, M.D.
National Comprehensive Cancer Network

Christopher R. Cogle, M.D.
University of Florida

Roger D. Dansey, M.D.
Merck

Nancy Davidson, M.D.
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

George D. Demetri, M.D.
Dana-Farber Cancer Institute

James H. Doroshow, M.D.
National Cancer Institute

Kojo Elenitoba-Johnson, M.D.
Perelman School of Medicine, University of Pennsylvania

Stanton L. Gerson, M.D.
Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center

Lori Hoffman Högg, M.S., R.N., CNS, AOCN
Veterans Health Administration

Linda House, R.N., BSN, MSM
Cancer Support Community

Hedvig Hricak, M.D., Ph.D.
Memorial Sloan Kettering Cancer Center

Lisa Kennedy Sheldon, Ph.D., APRN-BC, AOCNP, FAAN
Oncology Nursing Society

Samir Khleif, M.D.
Augusta University

Ronald M. Kline, M.D., FAAP
Centers for Medicare and Medicaid Services

Lee M. Krug, M.D.
Bristol-Myers Squibb

Francois Lafleur, MPH
Helsinn Therapeutics, Inc.

Michelle M. Le Beau, Ph.D.
University of Chicago Comprehensive Cancer Center

Mia Levy, M.D., Ph.D.
Vanderbilt-Ingram Cancer Center

Greta Massetti, Ph.D.
Centers for Disease Control and Prevention

Martin J. Murphy, Ph.D., D.Med.Sc.
CEO Roundtable on Cancer

Richard Pazdur, M.D.
Food and Drug Administration

Mace L. Rothenberg, M.D.
Pfizer Inc.

Richard L. Schilsky, M.D., FASCO
American Society of Clinical Oncology

Deborah Schrag, M.D., M.P.H.
Dana-Farber Cancer Institute

Lawrence N. Shulman, M.D.
University of Pennsylvania Abramson Cancer Center

Dan Theodorescu, M.D., Ph.D.
University of Colorado Cancer Center

George J. Weiner, M.D.
University of Iowa Holden Comprehensive Cancer Center

Robert A. Winn, M.D.
University of Illinois Health Cancer Center

Richard C. Woodman, M.D.
Novartis

Wendy A. Woodward, M.D., Ph.D.
The University of Texas MD Anderson Cancer Center

FORUM STAFF

Sharyl Nass, Ph.D.
Forum Director and Director,
Board on Health Care Services

Erin Balogh, M.P.H.
Senior Program Officer

Cyndi Trang, B.S.
Research Assistant

Natalie Lubin, B.A.
Senior Program Assistant

Patrick Burke, B.S.
Financial Officer

The National Academies of SCIENCES · ENGINEERING · MEDICINE

The nation turns to the National Academies of Sciences, Engineering, and Medicine for independent, objective advice on issues that affect people’s lives worldwide.
www.national-academies.org